Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face.
Rosen
A
A
Thimon
S
S
Ternant
D
D
Machet
M C
MC
Paintaud
G
G
Machet
L
L
D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005153:Facial Neoplasms / Q000188:drug therapy*; D005260:Female; D006394:Hemangiosarcoma / Q000188:drug therapy*; D006801:Humans; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab